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Background: Recent qualitative research has shown that stiffness is an important symptom for patients to identify
remission. However, it is unclear how to measure stiffness in low disease activity. This systematic review aims to
summarise the existing literature on validity of patient reported outcomes to measure stiffness in RA low disease
activity states, to aid the choice for a measurement instrument.
Methods: An extensive pubmed-search was undertaken, identifying measurement instruments for patient perceived
stiffness used in low disease activity. Eligible studies reported on 1) stiffness as an outcome in relation to other core
set measures, 2) development of a patient reported tool to measure stiffness, or 3) comparison of two different
tools to measure aspects of stiffness, all in low disease activity.
Results: Of 788 titles, only two studies report on validity of stiffness measures within low disease activity. Morning
stiffness (MS) is reported in 44 to 80% of patients in low disease activity. A difference of 40 to 60 minutes in
duration until maximum improvement is observed between active and inactive patients. Severity of MS might
discriminate better between high and low disease activity compared to measurement of duration of MS.
Conclusions: There is insufficient data on measurement of stiffness in the spectrum of low disease activity or
remission.
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Patients with rheumatoid arthritis (RA) often experience
stiffness of joints, especially in the morning or after pro-
longed rest. Morning stiffness (MS) in RA can be attributed
to the disrupted circadian rhythm of pro-inflammatory
cytokine release in RA [1]. As a consequence, symptoms
that follow the circadian rhythm like joint stiffness and
pain are most severe in the early mornings [2].
Duration of MS was part of the American classification
criteria for RA [3]. However, it was excluded from the re-
cent update, as it was felt the instruments to measure it
yielded data of insufficient reliability to include stiffness
in the classification criteria [4-9]. Still, impaired morning
function as a result of MS has considerable impact on the* Correspondence: L.vantuyl@vumc.nl
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stated.patients’ life. Severe stiffness in RA has been identified as
the most important predictor of early retirement, apart
from baseline working status [10]. A qualitative study
showed significant impact of impaired morning function
on quality of life, resulting in frustration and distress [11].
In addition, a strong inverse correlation between age and
MS has been identified, with younger patients assessing
their disease as more severe [12], pointing towards a
higher burden of MS for younger patients compared to
elderly patients. A qualitative study by Lineker et al. devel-
oped a patient-centered definition of MS in RA: ‘slowness
or difficulty moving the joints when getting out of bed or
after staying in one position too long, which involves both
sides of the body and gets better with movement’ [13].
Clearly, stiffness, either in the morning or during the
day, is an important aspect of RA disease activity.
However, not much is known about the role of stiff-
ness in low disease activity or remission. MS was part ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ponent of the new remission criteria for RA [15]. However,
a recent qualitative study into the patients’ perspective on
remission in RA showed that stiffness is an important as-
pect of the disease that needs to be reduced before one
would feel to be in remission [16].
To investigate stiffness in low disease activity states, a
valid measurement instrument is required. Cutolo re-
cently published a bibliographic study of current assess-
ment of morning stiffness, pain and function in RA [17].
Whilst a good overview of the current assessment and
reporting of stiffness, this study did not report on per-
formance of instruments in low disease activity.
With the current systematic review, we aim to sum-
marise the existing literature on validity of patient re-
ported outcomes to measure stiffness in RA low disease
activity or remission, to aid the choice for a measure-
ment instrument.
Methods
An extensive literature search identified existing, feas-
ible measurement instruments or subscales of existing
instruments for patient perceived stiffness, developed or
used within RA research. Identified studies were manu-
ally reviewed for evidence on performance of instru-
ments in low disease activity states.
Search strategy
We conducted a systematic literature search of Pubmed
on 20-11-2012 to identify studies presenting patient re-
ported measurement instruments that assess stiffness. No
limitations for language or year of publication were used.
The search was composed of three groups of search




2. Population Adults with rheumatoid arthritis
Mesh ((“Arthritis, Rheumatoid”[Mesh:NoExp] OR “Caplan
OR “Rheumatoid Nodule”[Mesh])
OR
Key words (Arthriti*[tiab] OR rheuma*[tiab] OR caplan[tiab] O
3. Instrument Patient reported outcome measures or instru
Key words (Questionnaire* OR scale OR instrument OR tool
PRO OR PROM)
4. Sensitive filter [18] 1 + 2 + 3 AND sensitive filter
5. exclusion filter [18] 4 NOT exclusion filter
*This symbol is used to search for all terms that start with this word.
Numbers 1 to 5 represent the different search blocks.measured, ie stiffness. The second group described the
disease, ie rheumatoid arthritis; the third group described
the type of instrument, ie patient reported measurement
instrument. These three groups were combined with a
sensitive, validated filter that was specifically designed to
identify studies on measurement properties in PubMed
[18]. Finally, an exclusion filter was added, to remove non-
relevant studies such as case reports, letters etc. The
search strategy was composed by one author (LvT) in con-
sultation with a medical information specialist (Table 1).
See Additional file 1 for the detailed search strategy.
Selection process and inclusion criteria
The selection of abstracts and full-text articles was done in
four phases; first, one author (LvT) screened all titles and
abstracts and selected titles that reported on either stiffness
or function, on measurement of patient reported outcomes
(PRO) or the development or validation of PRO instru-
ments. Secondly, two authors (LvT and MB) independently
from each other evaluated the remaining abstracts of the
possibly relevant studies by specifically selecting on popu-
lations with RA and reporting of measurement properties
of stiffness.
Thirdly, potentially relevant full articles were retrieved
and independently evaluated by the above authors. Arti-
cles were selected when they reported on stiffness in one
of the following ways:
1. stiffness as an outcome in relation to other core set
disease activity measures
2. the development of a patient reported tool to
measure stiffness
3. a comparison of two or more different tools to
measure aspects of stiffnessResult (hits)
32236
’s Syndrome”[Mesh]) OR “Felty’s Syndrome”[Mesh]) 77.890
R felty[tiab]) 172.447
188.044
ments i.e. questionnaires, scales, subscales, indexes
OR diary OR assessment OR self-report OR measure* OR 3.428.574
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as well as reviews on measures of stiffness were checked
for eligible studies.
Finally, the remaining articles, all reporting on aspects
of validity of stiffness measures, were searched for infor-
mation on performance in low disease activity or remis-
sion states by one author (LvT). See flowchart in Figure 1.
Data was extracted and summarised by one author
(LvT) and reviewed by a second author (MB).
Results
Of 788 titles, only 2 studies provide data on stiffness in
low disease activity and are included in this review. Mea-
surements are restricted to stiffness in the morning and
include measures of duration (both studies) and severity
(one study). Another 14 studies examined validity of stiff-
ness as a PRO in RA disease activity in general (Additional
file 2) [6,10,19-30]. The two studies in low disease activity
included in this review are summarized below.
Hazes et al. (1993) investigated different measures of
MS in 78 RA patients of median 60 years of age and a
median disease duration of 9 years [31]. Two measuresFigure 1 Flowchart of selection process.of MS severity and three measures of MS duration were
compared (Table 2). Patients were grouped as ‘active’
and ‘inactive’ based on the physicians subjective impres-
sion of active joint inflammation.
MS was reported by 89% of patients in active and 81%
in inactive disease. The duration of MS between the two
groups was similar, with no significant differences be-
tween the groups, pointing to a lack of discriminative
power of the three measures of MS duration. However,
patients with active disease reported more severe MS
than patients with inactive disease as measured by both
severity scales, reflecting better discriminative properties
for measures of severity vs measures of duration.
The sensitivity and specificity of the visual analogue
scale (VAS) to distinguish between active and inactive dis-
ease was 85% and 44% respectively at a cut off of VAS > 2.
In other words, with a MS VAS score of ≤2, there is a 44%
chance to classify a patient correctly as inactive.
Khan et al. (2009) [32] investigated the utility of MS
in assessing RA disease activity on data of the QUEST-
RA database. A total of 5439 RA patients from 24 differ-
ent countries and a mean disease duration of 11 years
Table 2 Identified measures of stiffness in rheumatoid arthritis low disease activity
First author + yr of publ Instrument and phrasing n
Hazes, 1993 [31] 1) Severity: 10 cm VAS ‘no’ to ‘very severe’ 78
2) Severity: NRS from 0 ‘no’ to 10 ‘very severe’.
3) Duration of MS (minutes):
1) ‘how long does you MS last until it begins to improve?’
2) ‘how long does your MS last until maximum improvement occurs?’
3) ‘how long does it take you to get going properly?’
Khan, 2009 [32] Duration of MS (minutes) in time from waking to time of max improvement in last week, in 4 categories: 5439
none, mild (1–30), moderate (31–60) and severe (>60)
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maximal improvement. MS was studied separately for 4
different disease activity states classified according to
DAS28 cut-offs for remission (<2.6), low (2.6 to ≤3.2),
moderate (3.2 < to ≤ 5.1), and high (>5.1). In addition,
the role of MS in Routine Assessment of Patient Index
Data 3 (RAPID3, composed of the core set PROs pain,
global health and physical functioning) to predict disease
activity according to the DAS28 was explored.
MS duration was significantly different for each disease
activity state, with the smallest difference (9 minutes) be-
tween low disease activity and remission. Although the
duration of MS increased with disease activity, even pa-
tients whose disease seemed to be under control reported
considerable duration of morning stiffness: of the 1594 pa-
tients with a DAS28 ≤ 3.2, 16% experienced morning stiff-
ness of more than half an hour, of which 46% with a
duration of more than one hour. Positive likelihood ratios
of having active disease for different MS duration categor-
ies rose from 0.35 (0 min) to 4 (>60 min).
The accuracy of MS to differentiate between active
and inactive disease (DAS28 cut off 3.2) was moderate,
represented by the area under the receiver operating
curve: 0.74 (0.72-0.75).
The relationship between RAPID3 and DAS28 was sig-
nificantly different for each MS duration category. Inter-
estingly, MS duration was especially valuable for RAPID3
scores representing low disease activity, where patients
with low RAPID3 scores but a DAS28 > 3.2 were identified
by presence of MS.
Discussion
This review identified 2 studies that investigated mea-
sures of stiffness in RA low disease activity states, both
focussed on morning stiffness. There are large differ-
ences between the 2 studies in patient characteristics as
well as in collection of outcome measures, making it dif-
ficult to draw overarching conclusions. Most import-
antly, this review highlights the lack of scientific data on
the performance of stiffness measures in low disease ac-
tivity states.Both studies included in this review show that despite
suppressed disease activity, morning stiffness is still
present; in the Hazes study, 89 vs 80% and in the Khan
study 79 vs 44% of active vs inactive patients report MS.
The study of Hazes et al. concludes that severity of
MS measured with a VAS or NRS scale can discriminate
between active and inactive disease, in contrast to mea-
sures of duration. On the other hand, Khan et al., show
that the same measure of duration (measured in minutes
from time of awaking to time of maximal improvement),
in a much larger sample of RA patients, does show mod-
erate discrimination between active and inactive RA. As
the two studies differ in several ways, conflicting conclu-
sions are not surprising. However, when looking closely,
both studies show a similar difference in MS duration
between active and inactive RA patients, with a differ-
ence of 60 minutes in the Hazes-study and 40 minutes
in the Khan-study. This means that the most likely ex-
planation for the difference in observations is the statis-
tical power of the studies to detect differences in duration
of MS between active and inactive patients, with the
Hazes-study including 78 patients and the Khan-study
5439 patients; however, differences can also be attributed
to differences in cut-off points for active and inactive RA
(physician based vs DAS28 based); or to a change in pa-
tients perception of stiffness over the years in comparison
to other RA symptoms and outcomes, as the Hazes study
was published in 1993 and the Khan study in 2009. More
research is needed to identify the best instrument to meas-
ure MS in low disease activity; not only focused on dis-
crimination between active and inactive RA, but also on
construct validity (whether low MS scores correlate with
low scores on other disease activity measures) and sensi-
tivity to pick up changes between low disease activity and
remission states.
A limitation of this review of the literature is the deci-
sion not to document evidence of response of stiffness
measures to therapy. As many studies do not mention
stiffness in title, abstract or keywords this would have re-
quired a full-text review of almost every RA intervention
study. Therefore, a specific search strategy was adopted
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search filter that is specially designed and validated for
finding studies on measurement properties of measure-
ment instruments [18].
Several studies provide evidence for validity of both dur-
ation as well as severity scales to measure stiffness, as both
generally show good correlation with core set measures
(especially pain and function) [19-22,27,28,30]. However,
problems arise when these measures are used to discrim-
inate RA from non-inflammatory conditions or osteoarth-
ritis [12,24,26,31]. Yet, this is only relevant when it is used
as a diagnostic criterion, which justifies the removal of
stiffness as a component of the ACR classification criteria.
In general, studies comparing measures of duration
with severity of stiffness show better measurement prop-
erties for severity in terms of sensitivity to change over
time, responsiveness to therapy and reliability [10,29,31].
This is confirmed by the Hazes study included in this re-
view, that shows discrimination between active and in-
active disease of severity scales but not for measurement
of duration of MS.
Qualitative studies investigating the concept of stiffness
in RA point to the strong connection between aspects of
stiffness and aspects of pain and physical functioning
[25,31]. This is confirmed by the Khan study, where MS
correlates better with physical function, pain and global
health than with joint counts or ESR. However, no specific
measurement instruments have been developed from these
qualitative explorations on the concept of stiffness. The
observation that MS duration adds important information
to predicting disease activity specifically at low RAPID3
scores is highly interesting, pointing to a possible dis-
tinguishing role for MS in classification of remission. To
evaluate the contribution of MS to the newly developed
ACR/EULAR remission criteria, new prospective studies
on the performance of different MS measures in the
spectrum of low disease activity are needed.Conclusion
In conclusion: while patients in low disease activity fre-
quently report stiffness, the tools to measure stiffness are
of unknown validity due to a lack of data on performance
of patient reported measures of stiffness in RA low disease
activity or remission.Additional files
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Additional file 2: Published articles on instruments or subscales of
instruments to measure stiffness.Competing interests
The authors have no competing interest concerning this study.Authors’ contributions
All authors (LH, WF, MB) have made substantial contributions to conception
and design, acquisition of data, analysis and interpretation of data; have
been involved in drafting the manuscript and have given final approval of
the version to be published.
Acknowledgements
This study was supported by an unconditional grant from Pfizer.
Author details
1Department of Rheumatology, VU University Medical Center, PO Box 7057,
1007 MB Amsterdam, The Netherlands. 2Department of Epidemiology and
Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB
Amsterdam, The Netherlands.
Received: 19 September 2013 Accepted: 21 January 2014
Published: 29 January 2014
References
1. Straub RH, Cutolo M: Circadian rhythms in rheumatoid arthritis:
implications for pathophysiology and therapeutic management.
Arthritis Rheum 2007, 56:399–408.
2. Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A: Circadian rhythms in
RA. Ann Rheum Dis 2003, 62:593–6.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al:
The American rheumatism association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315–24.
4. Anderson JJ, Felson DT, Meenan RF, Williams HJ: Which traditional
measures should be used in rheumatoid arthritis clinical trials?
Arthritis Rheum 1989, 32:1093–9.
5. Anderson JJ, Firschein HE, Meenan RF: Sensitivity of a health status measure
to short-term clinical changes in arthritis. Arthritis Rheum 1989, 32:844–50.
6. Buchbinder R, Bombardier C, Yeung M, Tugwell P: Which outcome
measures should be used in rheumatoid arthritis clinical trials? clinical
and quality-of-life measures’ responsiveness to treatment in a
randomized controlled trial. Arthritis Rheum 1995, 38:1568–80.
7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al:
2010 Rheumatoid arthritis classification criteria: an American college of
rheumatology/european league against rheumatism collaborative
initiative. Ann Rheum Dis 2010, 69:1580–8.
8. Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, et al:
The 2010 American college of rheumatology/European league against
rheumatism classification criteria for rheumatoid arthritis:
methodological report phase I. Ann Rheum Dis 2010, 2010(69):1589–95.
9. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, et al:
The 2010 American college of rheumatology/European league against
rheumatism classification criteria for rheumatoid arthritis: phase 2
methodological report. Arthritis Rheum 2010, 2010(62):2582–91.
10. Westhoff G, Buttgereit F, Gromnica-Ihle E, Zink A: Morning stiffness and its
influence on early retirement in patients with recent onset rheumatoid
arthritis. Rheumatology (Oxford) 2008, 47:980–4.
11. da Silva JA, Phillips S, Buttgereit F: Impact of impaired morning function
on the lives and well-being of patients with rheumatoid arthritis.
Scand J Rheumatol Suppl 2011, 125:6–11.
12. Yazici Y, Erkan D, Peterson MG, Kagen LJ: Morning stiffness: how common
is it and does it correlate with physician and patient global assessment
of disease activity? J Rheumatol 2001, 28:1468–9.
13. Lineker S, Badley E, Charles C, Hart L, Streiner D: Defining morning stiffness
in rheumatoid arthritis. J Rheumatol 1999, 26:1052–7.
14. Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in
rheumatoid arthritis. Arthritis Rheum 1981, 24:1308–15.
15. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al:
American college of rheumatology/European league against rheumatism
provisional definition of remission in rheumatoid arthritis for clinical
trials. Ann Rheum Dis 2011, 70:404–13.
16. van Tuyl LH, Hewlett S, Stamm T, Davis B, Flurey C, Hoogland W, et al: “Back
to being normal”: the patient perspective on remission in rheumatoid
arthritis [abstract]. Ann Rheum Dis 2013, 72(Suppl3):562.
17. Cutolo M: How should morning function in rheumatoid arthritis be
assessed? bibliographic study of current assessment. Scand J Rheumatol
2011, 125(Suppl):17–22.
van Tuyl et al. BMC Musculoskeletal Disorders 2014, 15:28 Page 6 of 6
http://www.biomedcentral.com/1471-2474/15/2818. Terwee CB, Jansma EP, Riphagen II, de Vet HC: Development of a
methodological PubMed search filter for finding studies on
measurement properties of measurement instruments. Qual Life Res 2009,
18:1115–23.
19. Borstlap M, Zant JL, van Soesbergen RM, van der Korst JK: Quality of life
assessment: a comparison of four questionnaires: for measuring
improvements after total hip replacement. Clin Rheumatol 1995, 14:15–20.
20. El Miedany Y, El GM, Youssef SS, Palmer D: Incorporating patient reported
outcome measures in clinical practice: development and validation of a
questionnaire for inflammatory arthritis. Clin Exp Rheumatol 2010,
28:734–44.
21. Fransen J, Langenegger T, Michel BA, Stucki G: Feasibility and validity of
the RADAI, a self-administered rheumatoid arthritis disease activity
index. Rheumatology (Oxford) 2000, 39:321–7.
22. Hazes JM, Hayton R, Burt J, Silman AJ: Consistency of morning stiffness: an
analysis of diary data. Br J Rheumatol 1994, 33:562–5.
23. Houssien DA, McKenna SP, Scott DL: The Nottingham health profile as a
measure of disease activity and outcome in rheumatoid arthritis.
Br J Rheumatol 1997, 36:69–73.
24. Leeb BF, Sautner J, Andel I, Rintelen B: SACRAH: a score for assessment
and quantification of chronic rheumatic affections of the hands.
Rheumatology (Oxford) 2003, 42:1173–8.
25. Rhind VM, Unsworth A, Haslock I: Assessment of stiffness in
rheumatology: the use of rating scales. Br J Rheumatol 1987, 26:126–30.
26. Wolfe F: Determinants of WOMAC function, pain and stiffness scores:
evidence for the role of low back pain, symptom counts, fatigue and
depression in osteoarthritis, rheumatoid arthritis and fibromyalgia.
Rheumatology (Oxford) 1999, 38:355–61.
27. Yazici Y, Pincus T, Kautiainen H, Sokka T: Morning stiffness in patients with
early rheumatoid arthritis is associated more strongly with functional
disability than with joint swelling and erythrocyte sedimentation rate.
J Rheumatol 2004, 31:1723–6.
28. Sarzi-Puttini P, Fiorini T, Panni B, Turiel M, Cazzola M, Atzeni F: Correlation
of the score for subjective pain with physical disability, clinical and
radiographic scores in recent onset rheumatoid arthritis.
BMC Musculoskelet Disord 2002, 19:18.
29. Vliet Vlieland TP, Zwinderman AH, Breedveld FC, Hazes JM: Measurement
of morning stiffness in rheumatoid arthritis clinical trials. J Clin Epidemiol
1997, 50:757–63.
30. Ward MM: Clinical measures in rheumatoid arthritis: which are most
useful in assessing patients? J Rheumatol 1994, 21:17–27.
31. Hazes JM, Hayton R, Silman AJ: A reevaluation of the symptom of
morning stiffness. J Rheumatol 1993, 20:1138–42.
32. Khan NA, Yazici Y, Calvo-Alen J, Dadoniene J, Gossec L, Hansen TM, et al:
Reevaluation of the role of duration of morning stiffness in the
assessment of rheumatoid arthritis activity. J Rheumatol 2009, 36:2435–42.
doi:10.1186/1471-2474-15-28
Cite this article as: van Tuyl et al.: Measurement of stiffness in patients
with rheumatoid arthritis in low disease activity or remission: a
systematic review. BMC Musculoskeletal Disorders 2014 15:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
